Lipid polymer hybrid carrier systems for cancer targeting: A review

Chaudhary, Zanib; Ahmed, Naveed; Rehman, Asim Ur; Khan, Gul Majid

doi:10.1080/00914037.2017.1300900

Cited by 35 publications

(21 citation statements)

References 111 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Hence, lipid-polymer hybrid nanoparticles (LPH) was designed, combining the advantages of both polymer-and lipid-based nanoparticles. LPH are archetype of nanocarriers composed of an internal polymeric core enclosed by an outer lipid bioactive shell composed of one or more layers or components [20,21]. By virtue of their unique structure, LPH have versatile competence to encapsulate different types of payloads such as hydrophilic, hydrophobic drugs or nucleic acids, highlighting promising in vivo therapeutic outcomes [22][23][24][25].…”

Section: Introductionmentioning

confidence: 99%

“…By virtue of their unique structure, LPH have versatile competence to encapsulate different types of payloads such as hydrophilic, hydrophobic drugs or nucleic acids, highlighting promising in vivo therapeutic outcomes [22][23][24][25]. The concomitance of both polymer and lipid imparts the LPH structural integrity, serum stability, sustained drug release (from the polymer core) and high biocompatibility (from the lipid shell) [21]. Finally, rapid opsonization induced by the lipidic shell resulting in rapid uptake of the particles by the mononuclear phagocyte system (MPS) in the liver and spleen has been previously proven [26,27].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

An integrated vitamin E-coated polymer hybrid nanoplatform: A lucrative option for an enhanced in vitro macrophage retention for an anti-hepatitis B therapeutic prospect

et al. 2020

View full text Add to dashboard Cite

A platform capable of specifically delivering an antiviral drug to the liver infected with hepatitis B is a major concern in hepatology. Vaccination has had a major effect on decreasing the emerging numbers of new cases of infection. However, the total elimination of the hepatitis B virus from the body requires prolonged therapy. In this work, we aimed to target the liver macrophages with lipid polymer hybrid nanoparticles (LPH), combining the merit of polymeric nanoparticles and lipid vesicles. The hydrophilic antiviral drug, entecavir (E), loaded LPH nanoparticles were optimized and physicochemically characterized. A modulated lipidic corona, as well as, an additional coat with vitamin E were used to extend the drug release enhance the macrophage uptake. The selected vitamin E coated LPH nanoparticles enriched with lecithin-glyceryl monostearate lipid shell exhibited high entrapment for E (80.47%), a size � 200 nm for liver passive targeting, extended release over one week, proven serum stability, retained stability after refrigeration storage for 6 months. Upon macrophage uptake in vitro assessment, the presented formulation displayed promising traits, enhancing the cellular retention in J774 macrophages cells. In vivo and antiviral activity futuristic studies would help in the potential application of the ELPH in hepatitis B control.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

An integrated vitamin E-coated polymer hybrid nanoplatform: A lucrative option for an enhanced in vitro macrophage retention for an anti-hepatitis B therapeutic prospect

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Cancer has been the most deleterious disease in recent times, and unfortunately its spread is increasing. Taking into account this grave health situation, scientists are trying to develop novel carriers for anticancer drug delivery specifically aimed at cancer tumors [1].…”

Section: Introductionmentioning

confidence: 99%

Polymers and Polymer Nanocomposites for Cancer Therapy

Feldman

2019

Applied Sciences

View full text Add to dashboard Cite

Synthetic polymers, biopolymers, and their nanocomposites are being studied, and some of them are already used in different medical areas. Among the synthetic ones that can be mentioned are polyolefins, fluorinated polymers, polyesters, silicones, and others. Biopolymers such as polysaccharides (chitosan, hyaluronic acid, starch, cellulose, alginates) and proteins (silk, fibroin) have also become widely used and investigated for applications in medicine. Besides synthetic polymers and biopolymers, their nanocomposites, which are hybrids formed by a macromolecular matrix and a nanofiller (mineral or organic), have attracted great attention in the last decades in medicine and in other fields due to their outstanding properties. This review covers studies done recently using the polymers, biopolymers, nanocomposites, polymer micelles, nanomicelles, polymer hydrogels, nanogels, polymersomes, and liposomes used in medicine as drugs or drug carriers for cancer therapy and underlines their responses to internal and external stimuli able to make them more active and efficient. They are able to replace conventional cancer drug carriers, with better results. Appl. Sci. 2019, 9, 3899 2 of 24 nanocomposites offer numerous opportunities in diverse applications, including nanocarriers, tissue engineering, antimicrobials, sensors, etc. These new groups of materials have gained significant research interest due to their novel properties, which are gained through the addition of nanofillers. Polymer nanocomposites have significant potential in disease theranostics, and nanotechnology brings great promise in cancer drug carriers [4].Chemotherapy implies the use of drugs and, besides the drugs, carriers. Common products used as carriers include synthetic polymers, biopolymers, and polymer nanocomposites.Some of the most useful drugs for chemotherapy are toxic chemicals able to inhibit the proliferation of cancer cells. The use of chemotherapeutic drugs has been in part hindered by their poor solubility in water, their short biological half-life, their lack of targeting ability, and the development of multidrug resistance [5]. In the last decades, nanoparticles have shown significant promise as an oncology treatment modality. Responsive polymers represent a promising class of nanoparticles that can trigger delivery through the exploitation of a specific stimuli. Response to a stimulus is one of the most basic processes found in living systems. A tutorial review highlighted the recent developments in polymer-based approaches to internally responsive nanoparticles for oncology [6].One important goal of medicine is to develop carriers that can selectively deliver anticancer drugs to tumor cells with no or minimal side effects in healthy cells [7,8].Polymers and their nanocomposites in different forms, such as micelles, hydrogels, polymersomes, and liposomes, have important potential in cancer diagnosis and treatment.Nanocomposites are popular in many areas due to properties such as their unique design capacity, eco-friendly nature, ...

show abstract

“…Notably, active targeting can provide enhanced delivery compared with passive targeting because of target specificity and molecular recognition. In active targeting, the outermost surface of the NPs is coated with different types of targeting ligands, such as antibodies, peptides, aptamers, and small molecules [ 65 ]. These targeting moieties are directly attached to the surface of PLHNPs either by strong chemical conjugation or via electrostatic interactions.…”

Section: Active Targeting With Surface Engineered Plhnpsmentioning

confidence: 99%

Utilization of Polymer-Lipid Hybrid Nanoparticles for Targeted Anti-Cancer Therapy

2020

View full text Add to dashboard Cite

Cancer represents one of the most dangerous diseases, with 1.8 million deaths worldwide. Despite remarkable advances in conventional therapies, these treatments are not effective to completely eradicate cancer. Nanotechnology offers potential cancer treatment based on formulations of several nanoparticles (NPs). Liposomes and polymeric nanoparticle are the most investigated and effective drug delivery systems (DDS) for cancer treatment. Liposomes represent potential DDS due to their distinct properties, including high-drug entrapment efficacy, biocompatibility, low cost, and scalability. However, their use is restricted by susceptibility to lipid peroxidation, instability, burst release of drugs, and the limited surface modification. Similarly, polymeric nanoparticles show several chemical modifications with polymers, good stability, and controlled release, but their drawbacks for biological applications include limited drug loading, polymer toxicity, and difficulties in scaling up. Therefore, polymeric nanoparticles and liposomes are combined to form polymer-lipid hybrid nanoparticles (PLHNPs), with the positive attributes of both components such as high biocompatibility and stability, improved drug payload, controlled drug release, longer circulation time, and superior in vivo efficacy. In this review, we have focused on the prominent strategies used to develop tumor targeting PLHNPs and discuss their advantages and unique properties contributing to an ideal DDS.

show abstract

Lipid polymer hybrid carrier systems for cancer targeting: A review

Cited by 35 publications

References 111 publications

An integrated vitamin E-coated polymer hybrid nanoplatform: A lucrative option for an enhanced in vitro macrophage retention for an anti-hepatitis B therapeutic prospect

An integrated vitamin E-coated polymer hybrid nanoplatform: A lucrative option for an enhanced in vitro macrophage retention for an anti-hepatitis B therapeutic prospect

Polymers and Polymer Nanocomposites for Cancer Therapy

Utilization of Polymer-Lipid Hybrid Nanoparticles for Targeted Anti-Cancer Therapy

Contact Info

Product

Resources

About